{
    "clinical_study": {
        "@rank": "124285", 
        "acronym": "CLASSIFY", 
        "arm_group": [
            {
                "arm_group_label": "Insulin Lispro Mix25", 
                "arm_group_type": "Experimental", 
                "description": "Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks."
            }, 
            {
                "arm_group_label": "Insulin Lispro Mix50", 
                "arm_group_type": "Experimental", 
                "description": "Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy and safety of insulin Lispro Mix25\n      (LM25) compared to insulin Lispro Mix50 (LM50) as an insulin starter in participants with\n      Type 2 diabetes mellitus (T2DM)."
        }, 
        "brief_title": "Comparison of Insulin Mix25 Versus Mix50", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of Type 2 Diabetes Mellitus for at least 6 months\n\n          -  Have been taking sulfonylureas, biguanide, thiazolidinedione, alpha-glucosidase\n             inhibitor, glinide, or dipeptidyl peptidase IV inhibitor, or any combination of these\n\n          -  Have a qualifying hemoglobin A1c value \u22657.0% and \u226411.0% at screening\n\n          -  Have a body mass index (BMI) \u226518.5 and <35.0 kilogram per square meter (kg/m^2)\n\n          -  Have given written informed consent to participate in the study in   accordance with\n             local regulations and the ethical review board (ERB) governing the study site\n\n        Exclusion Criteria:\n\n          -  Have a diagnosis of type 1 diabetes\n\n          -  Have had more than 1 episode of severe hypoglycemia within the 6 months before\n             screening\n\n          -  Have any of the following cardiovascular conditions within 3 months prior to\n             screening: acute myocardial infarction, New York Heart Association class III or class\n             IV heart failure, or cerebrovascular accident (stroke)\n\n          -  Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis,\n             or alanine aminotransferase levels \u22653.0 times the upper limit of the reference range\n             at screening, as determined by the central laboratory\n\n          -  Have an estimated creatinine clearance (CrCl), Cockcroft-Gault formula <30 milliliter\n             per minute (mL/min), as determined by the central laboratory at screening\n\n          -  Have evidence of a significant, active, uncontrolled endocrine or autoimmune\n             abnormality, as judged by the investigator\n\n          -  Have an active or untreated malignancy or have been in remission from a clinically\n             significant malignancy for <5 years\n\n          -  Have any other condition (such as, known drug or alcohol abuse or a psychiatric\n             disorder) that may prevent the participants from following and completing the\n             protocol\n\n          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical\n             trial involving an investigational product or non-approved use of a drug or device,\n             or concurrently enrolled in any other type of medical research judged not to be\n             scientifically or medically compatible with this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773473", 
            "org_study_id": "14675", 
            "secondary_id": "F3Z-CR-IOQI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin Lispro Mix25", 
                "description": "Administered SC", 
                "intervention_name": "Insulin Lispro Mix25", 
                "intervention_type": "Drug", 
                "other_name": "LY275585-75"
            }, 
            {
                "arm_group_label": "Insulin Lispro Mix50", 
                "description": "Administered SC", 
                "intervention_name": "Insulin Lispro Mix50", 
                "intervention_type": "Drug", 
                "other_name": "LY275585-50"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 1, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100029"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "zip": "410013"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "zip": "610041"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "zip": "404000"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "zip": "210028"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200092"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wulumuqi", 
                        "country": "China", 
                        "zip": "830000"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zhengzhou", 
                        "country": "China", 
                        "zip": "450052"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ibaraki", 
                        "country": "Japan", 
                        "zip": "302-0118"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kagoshima", 
                        "country": "Japan", 
                        "zip": "895-0052"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan", 
                        "zip": "242-0004"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miyagi", 
                        "country": "Japan", 
                        "zip": "985-0835"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagano", 
                        "country": "Japan", 
                        "zip": "399-0006"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okayama", 
                        "country": "Japan", 
                        "zip": "700-0013"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "530-0001"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan", 
                        "zip": "350-1305"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tochigi", 
                        "country": "Japan", 
                        "zip": "329-0433"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "206-0633"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yamaguchi", 
                        "country": "Japan", 
                        "zip": "751-0815"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "302-799"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "zip": "403-720"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeju Special Self-Governing Pr", 
                        "country": "Korea, Republic of", 
                        "zip": "690-767"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "137-701"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "zip": "442-723"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06500"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antalya", 
                        "country": "Turkey", 
                        "zip": "07070"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gaziantep", 
                        "country": "Turkey", 
                        "zip": "27070"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Japan", 
                "Korea, Republic of", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison Between Low Mixed Insulin and Mid Mixed Insulin AS Starter Insulin For Patients With TYpe 2 Diabetes Mellitus (CLASSIFY Study)", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Institutional Review Board", 
                "South Korea: Institutional Review Board", 
                "China: Ethics Committee", 
                "Turkey: Ministry of Health", 
                "India: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Hemoglobin A1c (HbA1c) at 26 Weeks", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 26 Weeks"
        }, 
        "removed_countries": {
            "country": "India"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773473"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants Achieving HbA1c of <7% or \u22646.5% at 26 Weeks", 
                "safety_issue": "No", 
                "time_frame": "26 Weeks"
            }, 
            {
                "measure": "Change from Baseline in Fasting Serum Glucose at 26 Weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 26 Weeks"
            }, 
            {
                "measure": "Change from Baseline in Body Weight at 26 Weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 26 Weeks"
            }, 
            {
                "measure": "Number of Hypoglycemic Events at 26 Weeks (Incidence)", 
                "safety_issue": "Yes", 
                "time_frame": "26 Weeks"
            }, 
            {
                "measure": "Insulin Dose at 26 Weeks", 
                "safety_issue": "No", 
                "time_frame": "26 Weeks"
            }, 
            {
                "measure": "Change from Baseline in 1,5-Anhydroglucitol (1,5-AG) at 26 Weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 26 Weeks"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}